Health Care

Read how Astellas Pharma’s $1.7 billion partnership with Vir Biotechnology could change prostate cancer treatment with the PSMA‑targeted VIR‑5500 dual‑masked T‑cell engager, boosting oncology innovation.

Rocket Pharmaceuticals is pushing gene‑therapy breakthroughs for rare pediatric diseases, trading around $4, with a 52‑week high of $9.84, a P/B of 1.30, and investor‑focused engagements at major healthcare conferences.

Novartis releases real‑world evidence boosting Pluvicto’s use for metastatic prostate cancer and faces shareholder‑driven CEO compensation review.

Repligen Corp’s Q4 2025 results show 18% revenue lift to $198 M and 14% organic growth, while 2026 guidance forecasts $810‑$840 M revenue and margin expansion.

Avanos Medical turns the corner: Q4 2025 shows a dramatic move from loss to modest profit, slashing debt and boosting margins while still chasing sustainable growth.

BioNTech sues Moderna in Delaware over mRNA patent, sparking a new legal battle amid vaccine efficacy gains and a growing oncology pipeline.

Johnson & Johnson’s latest legal battles, Blackstone partnership, and TREMFYA data reveal a resilient portfolio and rising analyst targets, keeping investors confident in its future growth.

Ocugen’s clinical‑stage biopharma journey: regenerative joint therapy, 2026 stock trends, upcoming earnings call, and investor outlook for biotech growth.

Discover how AQST’s delayed CNS drug approval and legal scrutiny shape its valuation and investor confidence, and what the upcoming Oppenheimer conference could mean for its future.

Ardelyx’s latest earnings reveal a biotech firm focused on GI‑centric metabolic drugs, trading at $5.73 with a $1.41B market cap and high investor confidence.